Waters Corp Embarks on a New Chapter with Becton Dickinson Partnership
In a move that’s sending shockwaves through the financial world, Waters Corp has announced a massive $17.5 billion deal with Becton Dickinson, a leading medical technology company. The partnership, which involves the merger of Waters’ Biosciences & Diagnostic Solutions unit with Becton Dickinson’s, is set to create a behemoth in the high-volume medical testing space.
The strategic move is expected to have a profound impact on Waters’ business, with the company’s total addressable market projected to double to approximately $40 billion. This growth is expected to be driven by an annual growth rate of 5-7%, making it an attractive opportunity for investors.
But what does this mean for Waters’ bottom line? According to projections, the combined company is expected to have pro forma sales of around $6.5 billion in 2025, with adjusted EBITDA of approximately $2.0 billion. These numbers are a testament to the potential of this partnership and the opportunities it presents for growth and expansion.
Key Highlights of the Partnership:
- Total addressable market expected to double to approximately $40 billion
- 5-7% annual growth rate
- Pro forma expected 2025 sales of around $6.5 billion
- Adjusted EBITDA of approximately $2.0 billion
As the dust settles on this massive deal, one thing is clear: Waters Corp is poised for a new chapter in its history. With this partnership, the company is well-positioned to take advantage of the growing demand for high-volume medical testing and capitalize on the opportunities presented by this strategic move.